CPT code 87797 represents a laboratory molecular diagnostic test using a direct nucleic acid probe technique to detect an infectious agent not otherwise specified by other CPT codes. It matters nationally because it provides a billing pathway for direct probe-based infectious agent testing when no specific agent code applies, supporting diagnostic flexibility in clinical microbiology and public health surveillance.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of code intent, typical clinical and laboratory contexts, and the payer landscape relevant to claims processing. The publication also outlines common modifiers used with the code, the typical service line for laboratory testing, and guidance on how this code fits within molecular diagnostic billing practices.

This summary provides operational clarity for billing teams and laboratory managers about where 87797 is used, what it represents clinically, and which national payers commonly adjudicate claims for direct probe infectious agent tests. Data not available in the input is noted where applicable in the detailed sections.